Pulmatrix (PULM)
(Delayed Data from NSDQ)
$2.13 USD
+0.04 (1.92%)
Updated Oct 16, 2024 03:59 PM ET
After-Market: $2.13 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.13 USD
+0.04 (1.92%)
Updated Oct 16, 2024 03:59 PM ET
After-Market: $2.13 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Pulmatrix, Inc. (PULM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -4.76% and 24.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -148.48% and 98.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 36.84% and 3.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulmatrix, Inc. (PULM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of -28.57% and -56.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bet on Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Pulmatrix, Inc. (PULM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of 22.22% and 47.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pulmatrix, Inc. (PULM) Q2 Earnings Expected to Decline
by Zacks Equity Research
Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck Announces Detailed Data on Late-Stage Cough Candidate
by Zacks Equity Research
Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.
Pulmatrix (PULM) Catches Eye: Stock Jumps 6%
by Zacks Equity Research
Pulmatrix (PULM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
The Wining Sector & Its Top Stocks in Virus-Infected January
by Sanghamitra Saha
January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.
Pulmatrix Surges on License Agreement With Johnson & Johnson
by Zacks Equity Research
Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix
by Zacks Equity Research
Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix
Bet on 5 Top Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.